

BelHealth Investment Partners Announces Recapitalization of Precision Toxicology

New York, NY – April 7, 2015 – BelHealth Investment Partners (“BelHealth”), a healthcare-focused private equity firm, announced the recapitalization of Precision Toxicology (“Precision” or the “Company”), a BelHealth portfolio company since May 2014. Monroe Capital LLC acted as sole lead arranger and administrative agent on the funding of a \$14.5 million senior credit facility to support the recapitalization and growth of Precision.

Precision Toxicology, based in San Diego, California, is a clinical laboratory that specializes in providing quantitative drug testing, primarily for the purpose of helping physicians monitor their patients who are undergoing treatment for pain or substance abuse. Precision’s objective is to improve patient adherence and compliance with their prescription regimen and protect medical practices from liability. The Company’s services help clients by monitoring appropriate use or identifying abuse of prescription drugs.

Dennis Drislane, BelHealth Managing Partner said, “We are pleased to partner with Monroe Capital on this transaction. Their group is highly experienced in the laboratory services market and we look forward to working with them to help Precision Toxicology continue its strong growth trajectory as a national competitor in the clinical diagnostic segment.”

Jason Hansen, Precision’s CEO added, “The new credit facility will provide us with increased flexibility as we continue to expand our customer base, increase our business and improve our technology. Our management team is excited to partner with Monroe through our next growth phase. BelHealth has helped immensely in attracting new institutional capital and positioning Precision for exponential future growth.”

About Precision Toxicology

Precision Toxicology, headquartered in San Diego, California, is a clinical laboratory that specializes in providing quantitative drug testing, primarily for the purpose of helping physicians monitor their patients undergoing treatment for pain or substance abuse. Precision’s objective is to improve patient adherence and compliance with their prescription regimen and protect medical practices from liability. The Company has experienced rapid growth since inception and will continue to expand its successful strategy throughout the rest of the country as a leading, national clinical toxicology lab.

About BelHealth Investment Partners

BelHealth Investment Partners, based in New York, is a healthcare private equity firm focused on lower middle market companies. BelHealth acquires majority positions in entrepreneur-owned companies we believe would benefit from our vast operating and private equity experience. The firm typically invests \$20-40 million per platform company across four healthcare segments: Services, Products, Distribution and Information Technology. Applying an active, hands-on approach, BelHealth utilizes its experience to support management to drive revenue, profit growth and achieve superior returns for our investors and partners.

For further information, please visit:

Precision Toxicology: www.precisiontoxicology.com

BelHealth Investment Partners: www.belhealth.com

Contact:

Precision Toxicology: Jason Hansen (800) 635-6901

BelHealth Investment Partners: David Sturek (347) 308-7019